Phase 2a Trial – Talk Bio

Rapport Therapeutics Reports Updated Phase 2a Data for Seizure Drug RAP-219

5 days ago talkbio0Tagged clinical seizure, Epilepsy, focal onset seizures, meeting, Phase 2a Trial, Phase 3 trials, RAP-219, Rapport Therapeutics, seizure drug, United States Food and Drug Administration

Rapport Therapeutics; RAP-219; Phase 2a trial; seizure drug; epilepsy; focal onset seizures; clinical seizure reduction; FDA meeting; Phase 3 trials

Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt

1 month ago talkbio0Tagged Biological Markers, Clinical Development, Neuroinflammation, NLRP3 inhibitor, Parkinson 's disease, Phase 2a Trial, VENT-02, Ventus Therapeutics

Ventus Therapeutics; VENT-02; NLRP3 inhibitor; Phase 2a trial; Parkinson’s disease; clinical development; neuroinflammation; biomarkers

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

3 months ago talkbio0Tagged Autoimmune Diseases, Clinical Research, Clinical trial failure, daisy, Imaavy, Johnson and Johnson, Nipocalimab, Phase 2a Trial, Rheumatoid Arthritis

Johnson & Johnson; Imaavy; nipocalimab; rheumatoid arthritis; Phase 2a trial; DAISY study; clinical trial failure; anti-TNFα therapy; autoimmune diseases

Immuneering’s Pancreatic Cancer Therapy Shows Promising Results in Phase 2a Trial, Stock Surges 55%

11 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, IMM-1, Immuneering, Inhibitor, MEK, Pancreatic carcinoma, Phase 2a Trial, surge

Immuneering, IMM-1-104, Pancreatic Cancer, Phase 2a Trial, MEK Inhibitor, Cancer Therapy, Clinical Trial Results, Stock Surge